

May 18, 2017

For the three-month period ended March 31, 2017, the performance of The Swiss Helvetia Fund, Inc. (the “Fund”), as measured by the change in value in the Fund’s net asset value (“NAV”), increased 8.66% in US dollars (“USD”). For the same period, the Fund’s share price performance increased 13.61% in USD, as the discount at which the Fund’s shares traded narrowed. This compares with an increase of 9.36% in the Swiss Performance Index (the “Index” or “SPI”) in USD.

### *Economic environment during the period under review*

#### *Global economic review*

The global macroeconomic environment remained mildly positive in the first quarter of 2017. The International Monetary Fund (“IMF”) did not materially change its forecast, expecting a moderate acceleration for developed markets, but also hinting at uncertainty due to the new United States (“US”) administration. Global Purchasing Manager Indices (“PMI”) softened from 53.9 to 53.5, but the manufacturing component strengthened. According to the latest European Central Bank economic bulletin, the Euro area recovery is becoming more broadly based and firmer – however that is from recessionary levels not long ago.

#### *Swiss economic review*

The Swiss economy as measured by GDP grew by 0.1% in the 4th quarter of 2016 (quarter on quarter; not annualized). Private and government consumption has had a positive impact, while investment in construction and


equipment has fallen slightly. The trade balance has also curbed GDP growth. On the production side, healthcare and social work as well as financial services have boosted growth, while value added in manufacturing and energy production has declined. For 2016 as a whole, real GDP grew by 1.3% (+0.8% in 2015). Due to the lower outcome in the second half of 2016, which was close to stagnation, expectations for 2017 were revised downwards to 1.6% from 1.8% by the State Secretariat for Economic Affairs (“SECO”) in March 2017. The SECO also expects unemployment to decline moderately to 3.2%.

### *Market environment during the period under review*

Equity markets extended their rally, which began with the November 2016 US election results. Returns were positive both in local currencies and Swiss francs for global, European, US and Swiss equities. In a departure from past trends, Swiss equities performed best among this group in local currency terms and on a currency adjusted basis. Normally, due to their defensive nature, Swiss equities tend to lag in a rising market. However, in the first quarter 2017, the SPI benefited from one of its most heavily weighted sectors, pharmaceuticals, which recovered by 11%, after having underperformed in 2016. Two sectors rose even more strongly, and no sub-sector was negative. This mix helped propel the SPI ahead of peer indices. Small & mid caps rose even more than large caps (11.7% compared to 8.9%).

## THE SWISS HELVETIA FUND, INC.

### Swiss Performance Index Q1 2017: Contributions to Index performance by sector\*



Source: Schroders, Bloomberg, as of March 31, 2017. Performance measured as total return in USD. Sectors mentioned should not be viewed as a recommendation to buy/sell. Portfolio composition is subject to change over time. Investors cannot invest directly in the Index.

### Performance

In comparing the Fund's NAV return of 8.66% to the Index's return of 9.36% in USD terms, there was a positive relative performance impact from some of the Fund's larger overweight positions, such as *Logitech*, *Belimo*, *DKSH*, *Sunrise*, *Swiss Life* and *VAT*.

Furthermore, being underweight in *Givaudan*, *Zurich Insurance*, *Swiss Re* and *Galenica* had a positive impact on relative performance. Some other underweights, however, had a negative effect on relative performance as they outperformed, namely *Actelion*, *Sika*, *ams*, *LafargeHolcim* and *Partners*

## THE SWISS HELVETIA FUND, INC.

*Group.* A number of negative contributions to relative performance came from overweights in *VZ Holding, Implenia, Tecan, GAM* and *Helvetia*.

The private equity positions as a whole experienced a minor positive re-valuation, reflecting a slight appreciation of the Swiss franc, partially offset by a valuation decrease for *Selfrac* to account for an additional financing round, in which the Fund did not participate, and its dilutive effect.

### *Portfolio changes*

In total, there were two purchases and five sales of listed equities on a net basis during the first quarter of 2017. As of March 31, 2017, there are 39 listed companies held by the Fund and seven direct private equity investments, including one participation in a private equity limited partnership.

<i>New Investments by the Fund</i>	<i>Positions Entirely Disposed of</i>
Aryzta	None
<i>Additions to Existing Investments</i>	<i>Reductions in Existing Investments</i>
UBS	Bucher Industries OC Oerlikon Logitech Swiss Re GAM

We bought a new position in *Aryzta* following the announcement that the executive management is stepping down. Furthermore, it was announced that the company will review its holding in *Piccard* and that *Aryzta* will start focusing on cash flows. We welcomed these changes by the new chairman as, in our opinion, *Aryzta* is an attractive asset that we think has been badly managed.

We increased the Fund's position in *UBS* as we believe it remains attractively valued.

We reduced our positions in *Bucher, GAM, OC Oerlikon, Logitech* and *Swiss Re*. We took profits in *Bucher* as the stock performed well in anticipation of an improvement in global dairy and commodity prices during 2017. We also used the ongoing strong share price performance of *Logitech* to realise some profits. Furthermore, we reduced our position in *Oerlikon* following the announcement of their full year result and their investment plans in additive manufacturing. *Oerlikon* plans to invest approximately CHF 300m to enter the additive manufacturing market. In our view, this venture in this new field

increases the company's risk profile. We took profits in GAM in anticipation of a weak result. We reduced the Fund's position in *Swiss Re*; we expect the re-insurance market to suffer a prolonged soft period as there is abundant capital at established and new players.

### *Outlook and Investment View*

Following the General Election results in the Netherlands and Macron's French Presidential win in May, investors will now look towards France's Parliamentary elections in June, and Germany's Federal election during the summer. Meanwhile, the European Central Bank's tone has turned more hawkish following the rise in headline inflation above its target. This is expected to be temporary and is unlikely to warrant a response from the Bank in the near term.

Despite a hostile approach with many members of the media, President Donald Trump remains in favor on Wall Street. The US equity market has returned just over 10% since the election on November 8th, outperforming the other major equity indices as well as cash, bonds and gold. Meanwhile, the UK equity market remains robust despite the government's recent decision to trigger Article 50 and set in motion the exit from the European Union. The fall in sterling clearly helped here, although more recently the rally has continued even as the pound has stabilized. On the face of it, last year's populist victories have been good for equity markets so far.

The rise in equity markets and bond yields reflects expectations of stronger growth driven by President Trump's deregulation agenda and his plans for fiscal expansion through tax cuts and infrastructure spending. Consequently, the outlook depends on his ability to deliver change and whether that change will boost activity. In terms of delivery, the recent healthcare bill is seen as a key test of his ability to get legislation through the system. Depending on that outcome, the path of other measures, such as tax cuts, may be more difficult.

So far then, equity markets have been robust under the new US administration. Investors have focused on the potential benefits of deregulation and fiscal stimulus. Deregulation has the potential to create opportunities, particularly in banking and the energy sector, although investors should be mindful of the prospect for higher inflation and interest rates. Our analysis of financial markets and economic cycles finds that a stagflationary mix, when inflation is rising as growth slows, often heralds a difficult period for investors as corporate earnings suffer and central banks seek to protect their inflation goals by tightening policy.

While these risks for equity markets may persist over the mid- to long-term horizon, and while equity markets have been positive since November 2016 and have relatively high valuation levels, we are maintaining a positive outlook (albeit with market volatility

on the rise). PMI on all major markets have improved considerably and indicate a pick-up in economic activity. Strong economic momentum from the end of last year is carrying over into 2017 in the US, Europe and Japan. Growth is also firming in the BRIC economies (Brazil, Russia, India and China) with China upgraded to 6.6% year-on-year and our global growth forecast has been nudged higher for 2017 to 2.9% (previously 2.8%). For 2018, consensus

growth forecast is unchanged at 3% as modest improvements in the BRICs, Japan and the UK are offset by a downgrade to the US where we have scaled back our expectations for fiscal expansion. In Switzerland, we expect an acceleration of growth in 2017.

Overall, this economic background should be beneficial for corporate earnings and ultimately supportive for equity markets.

THE SWISS HELVETIA FUND, INC.

Schedule of Investments by Industry (Unaudited)

March 31, 2017

No. of Shares	Security	Fair Value	Percent of Net Assets	No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Common Stock — 94.84%</b>							
<b>Banks — 11.35%</b>				<b>Banks — (continued)</b>			
<b>78,100</b>	<b>Cembra Money Bank AG<sup>1</sup></b> Provides financial services. The company's services include personal loans, vehicle financing, credit cards and savings and insurance services. (Cost \$4,692,948)	\$ 6,464,444	1.81%	<b>33,749</b>	<b>Valiant Holding AG</b> Provides financial services in Switzerland. The company offers a range of products and services in the areas of retail banking, business banking, private banking and asset management. (Cost \$3,430,305)	\$ 3,594,229	1.01%
<b>554,000</b>	<b>Credit Suisse Group AG<sup>1</sup></b> A global diversified financial services company with significant activity in private banking, investment banking and asset management. (Cost \$7,232,010)	8,246,765	2.32%			<u>40,428,132</u>	<u>11.35%</u>
<b>104,000</b>	<b>Julius Baer Group Ltd.<sup>1</sup></b> Provides private banking services. The company advises on wealth management, financial planning and investments; offers mortgage and other lending, foreign exchange, securities trading, custody and execution services. (Cost \$4,622,476)	5,195,065	1.46%	<b>Biotechnology — 3.11%</b>			
				<b>15,300</b>	<b>Actelion Ltd.<sup>1</sup></b> Focuses on the discovery, development and commercialization of treatments to serve critical, unmet medical needs. (Cost \$662,219)	4,321,205	1.21%
<b>1,057,000</b>	<b>UBS Group AG</b> Provides retail banking, corporate and institutional banking, wealth management, asset management and investment banking. (Cost \$16,046,126)	16,927,629	4.75%	<b>10,000</b>	<b>Basilea Pharmaceutica AG<sup>1</sup></b> Conducts research into the development of drugs for the treatment of infectious diseases and dermatological problems. (Cost \$670,410)	864,179	0.24%
				<b>93,160</b>	<b>Kuros Biosciences AG<sup>1</sup></b> Develops and produces biopharmaceuticals. The company produces vaccines that immunize the patient against disease related proteins. (Cost \$852,053)	1,675,288	0.47%

See Notes to Financial Statements.

THE SWISS HELVETIA FUND, INC.

Schedule of Investments by Industry (Unaudited)  
(continued)

March 31, 2017

No. of Shares	Security	Fair Value	Percent of Net Assets	No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Common Stock — (continued)</b>							
<b>Biotechnology — (continued)</b>							
11,400	<b>Lonza Group AG<sup>1</sup></b> Produces organic fine chemicals, biocides, active ingredients, and biotechnology products. The company operates production sites in China, Europe and the United States. (Cost \$826,233)	\$ 2,157,111	0.61%	80,000	<b>Implenia AG</b> Provides construction, civil and underground engineering services. The company's projects include residential and industrial buildings, tunnels, bridges and roads. The company also provides real estate and facilities management and marketing services. (Cost \$4,463,192)	\$ 5,618,662	1.58%
3,029	<b>Novimmune SA<sup>1,2</sup></b> Discovers and develops therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders. (Cost \$1,551,109)	2,051,713	0.58%			18,647,285	5.23%
		11,069,496	3.11%				
<b>Chemicals — 4.39%</b>							
35,400	<b>Syngenta AG</b> Produces herbicides, insecticides, fungicides, and seeds for field crops, vegetables and flowers. (Cost \$11,843,898)	15,635,486	4.39%				
		15,635,486	4.39%				
<b>Construction &amp; Materials — 5.23%</b>							
2,850	<b>Belimo Holding AG</b> Market leader in damper and volume control actuators for ventilation and air-conditioning equipment. (Cost \$5,722,519)	9,965,533	2.79%				
2,000	<b>Forbo Holding AG<sup>1</sup></b> Produces floor coverings, adhesives and belts for conveying and power transmission. (Cost \$2,300,431)	3,063,090	0.86%			7,760,414	2.18%
<b>Construction &amp; Materials — (continued)</b>							
<b>Financial Services — 2.18%</b>							
				219,254	<b>GAM Holding AG<sup>1</sup></b> An independent, well-diversified asset management business, with a focus on the manufacturing and distribution of investment products and services. (Cost \$3,082,403)	2,705,217	0.76%
				18,400	<b>VZ Holding AG</b> Provides independent financial advice to private individuals and companies. The company consults on investment, tax and inheritance planning and provides advice regarding insurance products and coverage. (Cost \$3,583,348)	5,055,197	1.42%

See Notes to Financial Statements.

THE SWISS HELVETIA FUND, INC.

Schedule of Investments by Industry (Unaudited)  
(continued)

March 31, 2017

No. of Shares	Security	Fair Value	Percent of Net Assets	No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Common Stock — (continued)</b>							
<b>Food &amp; Beverage — 17.69%</b>				<b>Industrial Goods &amp; Services — (continued)</b>			
130,700	<b>Aryzta AG<sup>1</sup></b> Produces and retails specialty bakery products. The Company produces French breads, pastries, continental breads, confections, artisan breads, homestyle lunches, viennoiserie, patisserie, cookies, pizza, appetizers, and sweet baked goods. (Cost \$4,306,186)	\$ 4,198,017	1.18%	25,000	<b>Burckhardt Compression Holding AG</b> Produces compressors for oil refining and the chemical and petrochemical industries, industrial gases and gas transport and storage. (Cost \$7,425,952)	\$ 6,774,814	1.90%
200	<b>Chocoladefabriken Lindt &amp; Spruengli AG</b> Major manufacturer of premium Swiss chocolates. (Cost \$3,409,877)	13,292,372	3.73%	54,006	<b>DKSH Holding AG</b> An international marketing and services group. The company offers a comprehensive package of services that includes organizing and running the entire value chain for any product. (Cost \$3,470,894)	4,181,493	1.17%
593,000	<b>Nestle SA</b> One of the world's largest food and beverage processing companies. (Cost \$13,894,380)	45,528,798	12.78%	45,000	<b>Feintool International Holding AG<sup>1</sup></b> Manufactures integrated systems for fineblanking and forming technologies. The company produces presses and special tooling capable of manufacturing precision parts, automation systems, riveting machines and extruded plastic and metal components. (Cost \$4,049,292)	5,295,969	1.49%
		63,019,187	17.69%	283,000	<b>OC Oerlikon Corp. AG<sup>1</sup></b> Produces industrial equipment to manufacture solar energy modules, place coatings, extract processing gases, manufacture textiles, and transmit power using mechatronic driveline components. (Cost \$2,859,300)	3,025,226	0.85%
<b>Industrial Goods &amp; Services — 7.06%</b>							
32,200	<b>Adecco Group AG</b> Provides personnel and temporary help, and offers permanent placement services internationally for professionals and specialists in a range of occupations. (Cost \$1,728,839)	2,288,856	0.64%				
3,005	<b>Bucher Industries AG</b> Manufactures food processing machinery, vehicles and hydraulic components. Produces fruit and vegetable juice processing machinery, farming machinery and outdoor equipment. (Cost \$751,002)	879,629	0.25%				

See Notes to Financial Statements.



THE SWISS HELVETIA FUND, INC.

Schedule of Investments by Industry (Unaudited)  
(continued)

March 31, 2017

No. of Shares	Security	Fair Value	Percent of Net Assets	No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Common Stock — (continued)</b>				<b>Machinery — 0.86%</b>			
<b>Industrial Goods &amp; Services — (continued)</b>				<b>28,293 VAT Group AG<sup>1</sup></b>			
28,500	<b>SFS Group AG<sup>1</sup></b> Provides automotive products, building and electronic components, flat roofing and solar fastening systems. The company operates production facilities in Asia, Europe and North America. (Cost \$1,849,976)	\$ 2,700,659	0.76%			\$ 3,083,837	0.86%
		25,146,646	7.06%			3,083,837	0.86%
<b>Insurance — 3.73%</b>				<b>Medical Equipment — 4.29%</b>			
5,500	<b>Helvetia Holding AG</b> Provides a broad range of life, casualty, liability, accident and transportation insurance. (Cost \$2,505,562)	3,049,603	0.86%	56,000	<b>Sonova Holding AG</b> Designs and produces wireless analog and digital in-the-ear and behind-the-ear hearing aids and miniaturized voice communications systems. (Cost \$8,573,645)	7,771,018	2.18%
24,500	<b>Swiss Life Holding AG<sup>1</sup></b> Provides life insurance and institutional investment management. (Cost \$5,607,319)	7,910,885	2.22%	3,731	<b>Spineart SA<sup>1,2</sup></b> Designs and markets an innovative full range of spine products, including fusion and motion preservation devices, focusing on easy to implant high-end products to simplify the surgical act. (Cost \$2,623,328)	969,139	0.27%
26,000	<b>Swiss Re AG</b> Provides reinsurance, insurance and insurance linked financial market products. The company offers automobile, liability, accident, engineering, marine, aviation, life and health insurance. (Cost \$2,221,228)	2,336,480	0.65%	41,000	<b>Tecan Group AG</b> Manufactures and distributes laboratory automation components and systems. The products are mainly used by research and diagnostic laboratories. (Cost \$3,806,154)	6,557,870	1.84%
		13,296,968	3.73%			15,298,027	4.29%

See Notes to Financial Statements.

THE SWISS HELVETIA FUND, INC.

Schedule of Investments by Industry (Unaudited)  
(continued)

March 31, 2017

No. of Shares	Security	Fair Value	Percent of Net Assets	No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Common Stock — (continued)</b>							
<b>Personal &amp; Household Goods — 5.27%</b>				<b>Retail — 0.53%</b>			
<b>145,000</b>	<b>Cie Financiere Richemont SA</b> Manufactures and retails luxury goods. Produces jewelry, watches, leather goods, writing instruments and men's and women's wear. (Cost \$9,612,861)	\$ 11,473,100	3.22%	<b>12,500</b>	<b>Dufry AG<sup>1</sup></b> Operates duty-free shops in countries such as Tunisia, Italy, Mexico, France, Russia, the United Arab Emirates, Singapore, the Caribbean and the United States. (Cost \$1,570,314)	\$ 1,905,689	0.53%
<b>105,000</b>	<b>Swatch Group AG (The)</b> Manufactures finished watches, movements and components. Produces components necessary to its various watch brand companies. The company also operates retail boutiques. (Cost \$9,126,647)	7,322,044	2.05%			1,905,689	0.53%
		18,795,144	5.27%	<b>Technology — 3.51%</b>			
				<b>170,000</b>	<b>Airopack Technology Group AG<sup>1</sup></b> Develops and patents packaging solutions. The company has developed a technology for filling liquids, powders, gases and products of average-to-high viscosity (such as gels, creams or foam) into recyclable plastic packaging. (Cost \$1,796,441)	1,936,161	0.54%
<b>Pharmaceuticals — 23.46%</b>				<b>332,300</b>	<b>Logitech International SA</b> Engages in the development and marketing of hardware and software products that enable or enhance digital navigation, music and video entertainment, gaming, social networking and audio and video communication. (Cost \$4,377,088)	10,573,710	2.97%
<b>580,000</b>	<b>Novartis AG</b> One of the leading manufacturers of branded and generic pharmaceutical products. (Cost \$13,932,329)	43,082,072	12.09%			12,509,871	3.51%
<b>158,500</b>	<b>Roche Holding AG</b> Develops and manufactures pharmaceutical and diagnostic products. Produces prescription drugs to treat cardiovascular, infectious and autoimmune diseases and for other areas including dermatology and oncology. (Cost \$10,459,225)	40,505,819	11.37%				
		83,587,891	23.46%				

See Notes to Financial Statements.

THE SWISS HELVETIA FUND, INC.

Schedule of Investments by Industry (Unaudited)  
(continued)

March 31, 2017

No. of Shares	Security	Fair Value	Percent of Net Assets	No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Common Stock — (continued)</b>				<b>Preferred Stock — (continued)</b>			
<b>Telecommunications — 2.18%</b>				<b>Industrial Goods &amp; Services — 0.05%</b>			
102,800	<b>Sunrise Communications Group AG<sup>1</sup></b> Provides a broad range of telecommunications services and equipment. The company offers mobile and wired phone services, broadband internet, cable television services, mobile phones, tablet computers and related equipment. (Cost \$7,266,158)	\$ 7,754,034	2.18%	500,863	<b>Selfrag AG Class A<sup>1,2</sup></b> Designs, manufactures and sells industrial machines and processes using selective fragmentation technology. (Cost \$1,932,198)	\$ 185,144	0.05%
		7,754,034	2.18%			185,144	0.05%
	<b>Total Common Stock</b> (Cost \$200,154,316)	337,938,107	94.84%			68,496	0.02%
<b>Preferred Stock — 0.71%</b>				<b>Medical Equipment — 0.02%</b>			
<b>Biotechnology — 0.64%</b>				<b>Limited Partnership — 0.29%</b>			
8,400	<b>Ixodes AG, Series B<sup>1,2,3</sup></b> Develops and produces a topical product for the treatment of borreliosis infection and the prevention of Lyme disease from a tick bite. (Cost \$2,252,142)	139,224	0.04%				
3,162	<b>Novimmune SA, Series B<sup>1,2</sup></b> Discovers and develops therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders. (Cost \$2,062,307)	2,141,801	0.60%				
		2,281,025	0.64%				
				<b>Total Preferred Stock</b> (Cost \$9,253,695)			
				<b>Aravis Biotech II, Limited Partnership<sup>1,2,3</sup></b> (Cost \$2,688,778)			
				<b>Total Limited Partnership</b> (Cost \$2,688,778)			
				<b>Total Investments*</b> (Cost \$212,096,789)			
				<b>Other Assets Less Liabilities</b>			
				<b>Net Assets</b>			
				<b>Net Asset Value Per Share:</b> (\$356,317,373 ÷ 28,126,525 shares outstanding, \$0.001 par value; 50 million shares authorized)			
				\$ 12.67			
						2,534,665	0.71%
						14,820,403	4.16%
						\$356,317,373	100.00%

See Notes to Financial Statements.

THE SWISS HELVETIA FUND, INC.

Schedule of Investments by Industry (Unaudited)  
(continued)

March 31, 2017

<sup>1</sup> Non-income producing security.

<sup>2</sup> Illiquid. There is not a public market for these securities in the United States or in any foreign jurisdiction, including Switzerland. Securities are priced at Fair Value in accordance with the Fund's valuation policy and procedures. At the end of the period, the aggregate Fair Value of these securities amounted to \$6,579,715 or 1.8% of the Fund's net assets. Additional information on these securities is as follows:

<u>Security</u>	<u>Acquisition Date</u>	<u>Cost</u>
Aravis Biotech II, Limited Partnership	July 31, 2007 – September 13, 2016	\$ 2,688,778
EyeSense AG – Preferred Shares A	July 22, 2010 – October 3, 2011	3,007,048
Ixodes AG – Preferred Shares B	April 7, 2011 – June 1, 2012	2,252,142
NovImmune SA – Common Shares	October 7, 2009 – December 11, 2009	1,551,109
NovImmune SA – Preferred Shares B	October 7, 2009 – December 11, 2009	2,062,307
Selfrag AG – Class A – Preferred Shares	December 15, 2011 – January 28, 2014	1,932,198
Spineart SA – Common Shares	December 22, 2010	<u>2,623,328</u>
		<u>\$16,116,910</u>

<sup>3</sup> Affiliated Company. An affiliated company is a company in which the Fund has ownership of at least 5% of the company's outstanding voting securities or an equivalent interest in the company. Details related to affiliated company holdings are as follows:

<u>Name of Issuer</u>	<u>Fair Value as of 12/31/16</u>	<u>Gross Additions</u>	<u>Gross Reductions</u>	<u>Realized Gain/(Loss)</u>	<u>Change in Unrealized Gain/(Loss)</u>	<u>Interest Income</u>	<u>Fair Value as of 03/31/17</u>
Aravis Biotech II, Limited Partnership	\$ 966,400	\$—	\$—	\$—	\$57,798	\$—	\$1,024,198
Ixodes AG – Preferred Shares B	137,114	—	—	—	2,110	—	139,224
	<u>\$1,103,514</u>	<u>\$—</u>	<u>\$—</u>	<u>\$—</u>	<u>\$59,908</u>	<u>\$—</u>	<u>\$1,163,422</u>

\* Cost for Federal income tax purposes is \$212,202,033 and net unrealized appreciation (depreciation) consists of:

Gross Unrealized Appreciation	\$143,165,239
Gross Unrealized Depreciation	(13,870,302)
Net Unrealized Appreciation (Depreciation)	<u>\$129,294,937</u>

See Notes to Financial Statements.

---

THE SWISS HELVETIA FUND, INC.

---

Schedule of Investments by Industry (Unaudited)  
(concluded)

March 31, 2017

**PORTFOLIO HOLDINGS**

**% of Net Assets as of March 31, 2017**

Pharmaceuticals	23.46%
Food & Beverage	17.69%
Banks	11.35%
Industrial Goods & Services	7.11%
Personal & Household Goods	5.27%
Construction & Materials	5.23%
Chemicals	4.39%
Medical Equipment	4.31%
Biotechnology	4.04%
Insurance	3.73%
Technology	3.51%
Financial Services	2.18%
Telecommunications	2.18%
Machinery	0.86%
Retail	0.53%
Other Assets Less Liabilities	4.16%
	<u>100.00%</u>

**TOP 10 PORTFOLIO HOLDINGS**

**% of Net Assets as of March 31, 2017**

Nestle SA	12.78%
Novartis AG	12.09%
Roche Holding AG	11.37%
UBS Group AG	4.75%
Syngenta AG	4.39%
Chocoladefabriken Lindt & Spruengli AG	3.73%
Cie Financiere Richemont SA	3.22%
Logitech International SA	2.97%
Belimo Holding AG	2.79%
Credit Suisse Group AG	2.32%

---

See Notes to Financial Statements.

## Notes to Schedule of Investments (Unaudited)

### Note 1—Organization and Significant Accounting Policies

#### A. Organization

The Swiss Helvetia Fund, Inc. (the “Fund”) is registered under the Investment Company Act of 1940, as amended (the “Act”), as a non-diversified, closed-end management investment company. The Fund is organized as a corporation under the laws of the State of Delaware.

The investment objective of the Fund is to seek long-term growth of capital through investment in equity and equity-linked securities of Swiss companies. The Fund may also acquire and hold equity and equity-linked securities of non-Swiss companies in limited instances.

#### B. Securities Valuation

The Fund values its investments at fair value in accordance with accounting principles generally accepted in the United States (“GAAP”).

When valuing listed equity securities, the Fund uses the last sale price on the securities exchange or national securities market on which such securities primarily are traded (the “Primary Market”) prior to the calculation of the Fund’s net asset value (“NAV”). When valuing equity securities that are not listed (except privately-held companies and private equity limited partnerships) or that are listed but have not traded on a day on which the Fund calculates its NAV, the Fund uses the mean between the bid and asked prices for that day. If there are no asked quotations for such a security, the value of such security will be the most recent bid quotation on the Primary Market on that day. On any day when a security’s Primary Market is closed because of a local holiday or other scheduled closure, but the New York Stock Exchange is open, the Fund may use the prior day’s closing prices to value such security regardless of the length of the scheduled closing.

When valuing fixed-income securities, if any, the Fund uses the last bid price prior to the calculation of the Fund’s NAV. If there is no current bid price for a fixed-income security, the value of such security will be the mean between the last quoted bid and asked prices on that day. Overnight and certain other short-term fixed-income securities with maturities of less than 60 days will be valued by the amortized cost method, unless it is determined that the amortized cost method would not represent the fair value of such security.

It is the responsibility of the Fund’s Board of Directors (the “Board”) to establish procedures to provide for the valuation of the Fund’s portfolio holdings. When valuing securities for which market quotations are not readily available, or for which the market quotations that are available are considered unreliable, the Fund determines a fair value in good faith in accordance with these procedures (a “Fair Value”). The Fund may use these procedures to establish the Fair Value of securities when, for example, a significant event occurs between the time the market closes and the time the Fund values its investments. After consideration of various factors, the Fund may value the securities at their last reported price or at some other value.

Swiss exchange-listed options, if any, including Eurex-listed options, are valued at their most recent sale price (latest bid for long options and the latest ask for short options) on the Primary Market, or if there are no such sales, at the average of the most recent bid and asked quotations on such Primary Market, or if such quotations are not available, at the last bid quotation (in the case of purchased options) or the last asked quotation (in the case of written options). If, however, there are no such quotations, such options will be valued using the implied volatilities observed for similar options or from aggregated data as an input to a model. Options traded in the over-the-counter market, if any, are valued at the price communicated by the counterparty to the option, which typically is the price at which the counterparty would close out the transaction. Option contracts, if any, that are neither exchange-listed nor traded in the over-the-counter market, and where no broker can provide a quote or approved pricing vendor a price, may be valued using the implied volatilities observed for similar instruments or from aggregated market data received from services (e.g., Bloomberg) as an input to a widely-accepted model.

## THE SWISS HELVETIA FUND, INC.

### Notes to Schedule of Investments (Unaudited) (continued)

The Fund is permitted to invest in investments that do not have readily available market quotations. For such investments, the Act requires the Board to determine their Fair Value. The aggregate value of these investments amounted to \$6,579,715, or 1.8% of the Fund's net assets at March 31, 2017, and are listed in Note 2 to the Schedule of Investments.

Various inputs are used to determine the value of the Fund's investments. These inputs are summarized in the three broad levels listed below:

Level 1—unadjusted quoted prices in active markets for identical assets and liabilities

Level 2—other significant observable inputs (including quoted prices of similar securities, interest rates, prepayment speeds, credit risk, etc.)

Level 3—significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments)

The inputs or methodology used for valuing securities are not an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used to value the Fund's investments as of March 31, 2017:

	Level 1 Quoted Prices	Level 2 Other Significant Observable Inputs	Level 3 Significant Unobservable Inputs	Investment Valued at NAV**	Total
<b>Investments in Securities*</b>					
Common Stock	\$334,917,255	\$—	\$3,020,852	\$ —	\$337,938,107
Preferred Stock	—	—	2,534,665	—	2,534,665
Limited Partnership	—	—	—	1,024,198	1,024,198
<b>Total Investments in Securities</b>	<u>\$334,917,255</u>	<u>\$—</u>	<u>\$5,555,517</u>	<u>\$1,024,198</u>	<u>\$341,496,970</u>

\* Please see the Schedule of Investments for industry classifications.

\*\* The Fund adopted Accounting Standards Update 2015-07, Fair Value Measurement (Topic 820): Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent) ("ASU 2015-07") on January 1, 2016. As of March 31, 2017 certain of the Fund's investments were valued using net asset value ("NAV") per share (or its equivalent) as a practical expedient for fair value and have been excluded from the fair value hierarchy in accordance with ASU 2015-07. The fair value amount presented in this table is intended to permit reconciliation of the amounts presented in the fair value hierarchy to the amounts presented in the statement of assets and liabilities.

The Fund values its investment in a private equity limited partnership in accordance with Accounting Standards Codification 820-10-35, "Investments in Certain Entities that Calculate Net Asset Value Per Share (Or its Equivalent)" ("ASC 820-10-35"). ASC 820-10-35 permits a reporting entity to measure the fair value of an investment that does not have a readily determinable fair value, based on the NAV of the investment as a practical expedient, without further adjustment, unless it is probable that the investment will be sold at a value significantly different than the NAV. If the NAV of the investment is not as of the Fund's measurement date, then the NAV should be adjusted to reflect any significant events that may change the valuation. Inputs and valuation techniques for these adjustments may include fair valuations of the partnership and its portfolio holdings provided by the partnership's general partner or manager, other available information about the partnership's portfolio holdings, values obtained on redemption from other limited partners, discussions with the partnership's general partner or manager and/or other limited partners and comparisons of previously-obtained estimates to the partnership's audited financial statements. In using the unadjusted NAV as a practical expedient, certain attributes of the investment that may impact its fair value are not considered. Attributes of those investments include the investment strategies of the privately-held companies and may also include, but are not limited to, restrictions on the investor's ability to redeem its investments at the measurement date and any unfunded commitments.

Level 3 securities, which are listed in Note 2 to the Schedule of Investments, consist of the Fund's investments in privately-held companies.

## THE SWISS HELVETIA FUND, INC.

### Notes to Schedule of Investments (Unaudited) (continued)

Inputs and valuation techniques used by the Fund to value its Level 3 investments in privately-held companies may include the following: acquisition cost; fundamental analytical data; discounted cash flow analysis; nature and duration of restrictions on disposition of the investment; public trading of similar securities of similar issuers; economic outlook and condition of the industry in which the issuer participates; financial condition of the issuer; and the issuer's prospects, including any recent or potential management or capital structure changes. Although these valuation inputs may be observable in the marketplace as is characteristic of Level 2 investments, the privately-held companies, categorized as Level 3 investments, generally are highly illiquid in terms of resale.

When valuing Level 3 investments, management also may consider potential events that could have a material impact on the operations of a privately-held company. Not all of these factors may be considered or available, and other relevant factors may be considered on an investment-by-investment basis. The table below summarizes the techniques and unobservable inputs for the valuation of Level 3 investments.

Quantitative Information about certain Level 3 Fair Value Measurements

	Fair Value at March 31, 2017	Valuation Technique	Unobservable inputs	Range <sup>1</sup>
<i>Biotechnology</i>				
NovImmune SA—Common Shares	\$2,051,713	Market approach	Recent round of financing	N/A
NovImmune SA—Preferred Shares	2,141,801	Market approach	Recent round of financing	N/A
Ixodes AG—Preferred Shares	139,224	Discounted cash flow	Discount rate Probability of success rate on research and development	14%-16% 40%-60%
<i>Industrial Goods &amp; Services</i>				
Selfrag AG—Preferred Shares	185,144	Market approach	Recent round of financing	N/A
<i>Medical Equipment</i>				
EyeSense AG—Preferred Shares	68,496	Market approach	Recent round of financing	N/A
Spineart SA—Common Shares	969,139	Market approach	Recent round of financing	N/A
<b>Total</b>	<b>\$5,555,517</b>			

<sup>1</sup> Significant changes in any of these ranges would result in a significantly higher or lower fair value measurement. Generally, a change in the probability of success rate on research and development is accompanied by a directionally similar change in fair value. Conversely, a change in the discount rate is accompanied by a directionally opposite change in fair value.

The Fund's policy is to disclose transfers between Levels based on their market prices as of the beginning of the period.

The following is a reconciliation of Level 3 assets for which significant unobservable inputs were used to determine fair value.

	Common Stock	Preferred Stock	Total
Balance as of December 31, 2016	\$2,975,080	\$2,525,827	\$5,500,907
Change in Unrealized Appreciation/Depreciation (a)	45,772	8,838	54,610
Net Realized Gain (Loss)	—	—	—
Gross Purchases	—	—	—
Gross Sales	—	—	—
Transfer Out of Level 3	—	—	—
<b>Balance as of March 31, 2017</b>	<b>\$3,020,852</b>	<b>\$2,534,665</b>	<b>\$5,555,517</b>

(a) The noted amounts of change in unrealized appreciation/depreciation relate to the fair value of Level 3 assets held on March 31, 2017.



## THE SWISS HELVETIA FUND, INC.

### Notes to Schedule of Investments (Unaudited) (concluded)

#### C. Foreign Currency Translation

The Fund maintains its accounting records in U.S. dollars. The Fund's assets are invested primarily in Swiss equities. In addition, the Fund can make its temporary investments in Swiss franc-denominated bank deposits, short-term debt securities and money market instruments. Substantially all income received by the Fund is in Swiss francs. The Fund's NAV, however, is reported, and distributions from the Fund are made, in U.S. dollars, resulting in gain or loss from currency conversions in the ordinary course of business. Historically, the Fund has not entered into transactions designed to reduce currency risk and does not intend to do so in the future. The cost basis of foreign denominated assets and liabilities is determined on the date that they are first recorded within the Fund and translated to U.S. dollars. These assets and liabilities are subsequently valued each day at prevailing exchange rates. The difference between the original cost and current value denominated in U.S. dollars is recorded as unrealized foreign currency gain/loss. In valuing securities transactions, the receipt of income and the payment of expenses, the Fund uses the prevailing exchange rate on the transaction date.

#### D. Concentration of Market Risk

The Fund primarily invests in securities of Swiss issuers. Such investments may carry certain risks not ordinarily associated with investments in securities of U.S. issuers. These risks include future political and economic developments, unfavorable movements in the Swiss franc relative to the U.S. dollar, and the possible imposition of exchange controls and changes in governmental law and restrictions. In addition, concentrations of investments in securities of issuers located in a specific region expose the Fund to the economic and government policies of that region and may increase risk compared to a fund whose investments are more diversified.

#### Note 2—Capital Commitments

As of March 31, 2017, the Fund maintains an illiquid investment in one private equity limited partnership. This investment appears in the Fund's Schedule of Investments. The Fund's capital commitment for this partnership is shown in the table below:

<u>Investments</u>	<u>Original Capital Commitment*</u>	<u>Unfunded Commitment*</u>
<b>Private Equity Limited Partnership—International (a)</b>		
Aravis Biotech II, Limited Partnership	\$3,246,915	\$139,293

\* The original capital commitment represents 3,250,000 Swiss francs. The unfunded commitment represents 139,425 Swiss francs.

The Swiss franc/U.S. dollar exchange rate as of March 31, 2017 was used for conversion and equaled 1.00095 as of such date.

(a) This category consists of one private equity limited partnership that invests primarily in ventures, biotechnology and in management buyout of industrial and consumer goods companies. There is no redemption right for the interest in this limited partnership. Instead, the nature of investments in this category is that distributions are received through the realization of the underlying assets of the limited partnership.

#### Note 3—Subsequent Events

On March 28, 2017, the Fund commenced a self-tender offer (the "Offer") for up to 2,812,653 of its issued and outstanding shares of common stock, which represented approximately 10% of the Fund's issued and outstanding shares as of the commencement of the Offer, at a price per share equal to 98% of the Fund's NAV determined as of the close of the regular trading session of the New York Stock Exchange ("NYSE") on the business day immediately following the day the Offer expired. The Offer expired at 5:00 p.m., New York time, on April 24, 2017.

Approximately 17,795,965 shares of common stock, or approximately 63% of the Fund's outstanding shares as of the commencement of the Offer, were properly tendered. The Fund accepted 2,812,653 shares, or approximately 15.8% of the shares tendered, on a prorated basis, for cash payment of \$12.85 per share, which represented 98% of the Fund's NAV per share as of the close of regular trading session of the NYSE on April 25, 2017.

## Automatic Dividend Reinvestment Plan (Unaudited)

### Terms and Conditions

Pursuant to this Automatic Dividend Reinvestment Plan (the "Plan") of The Swiss Helvetia Fund, Inc. (the "Fund"), unless a holder (each, a "Shareholder") of the Fund's shares of common stock (the "Common Shares") otherwise elects, all income dividends, capital gain distributions and returns of capital, if any (collectively referred to herein as "dividends"), on such Shareholder's Common Shares will be automatically reinvested by American Stock Transfer & Trust Company, as agent for Shareholders in administering the Plan (the "Plan Administrator"), in additional Common Shares of the Fund. Shareholders who elect not to participate in the Plan will receive all dividends payable in cash directly to the Shareholder of record (or, if the Common Shares are held in street or other nominee name, then to such nominee) by American Stock Transfer & Trust Company LLC, as the Dividend Disbursing Agent. Shareholders may elect not to participate in the Plan and to receive all dividends in cash by contacting the Plan Administrator. Enrollment, purchase or sales of shares and other transactions or services offered by the Plan can be directed to the Plan Administrator through the following:

### Telephone

Telephone the Plan Administrator: 1-888-556-0425.

### In Writing

You may also write to the Plan Administrator at the following address: American Stock Transfer & Trust Company, PO Box 922, Wall Street Station, New York, NY 10269-0560. Be sure to include your name, address, daytime phone number, social security or tax I.D. number and a reference to The Swiss Helvetia Fund, Inc. on all correspondence.

Participation in the Plan is completely voluntary and may be terminated at any time without penalty by providing notice in writing to the Plan Administrator at least 3 business days prior to any dividend payment date for that dividend to be payable in cash. A request for termination that is received less than 3 business days prior to any dividend payment date will be processed by the Plan Administrator, but you will have that dividend reinvested in additional Common Shares. However, all subsequent dividends will be payable in cash unless and until you resume participation in the Plan. To resume participation in the Plan, your request to enroll in the Plan must be received by the record date for that dividend distribution. If received after the record date, your participation in the Plan will begin with the next dividend declaration.

Whenever the Fund declares a dividend, payable either in Common Shares or in cash, participants in the Plan will receive a number of Common Shares determined in accordance with the following provisions and non-participants in the Plan will receive cash. The Common Shares will be acquired by the Plan Administrator for the participants' accounts, depending upon the circumstances described below, either (i) through the receipt of additional unissued but authorized Common Shares from the Fund ("newly issued Common Shares") or (ii) by purchase of outstanding Common Shares on the open market ("open-market purchases") on the New York Stock Exchange, the primary national securities exchange on which the Common Shares are traded, or elsewhere.

If, on the payment date for any dividend, the net asset value ("NAV") per Common Share is equal to or less than the market price per Common Share (plus estimated brokerage trading fees) (such condition being referred to herein as "market premium"), the Plan Administrator will

### Automatic Dividend Reinvestment Plan (Unaudited) (continued)

invest the dividend amount in newly issued Common Shares on behalf of the participants. The number of newly issued Common Shares to be credited to each participant's account will be determined by dividing the dollar amount of the dividend by the NAV per Common Share on the date the Common Shares are issued, provided that, if the NAV per Common Share is less than or equal to 95% of the then current market price per Common Share on the date of issuance, the dollar amount of the dividend will be divided by 95% of the market price on the date of issuance for purposes of determining the number of shares issuable under the Plan.

If, on the payment date for any dividend, the NAV per Common Share is greater than the market price of the Common Shares (plus estimated brokerage trading fees) (such condition being referred to herein as "market discount"), the Plan Administrator will invest the dividend amount in Common Shares acquired on behalf of the participants in open-market purchases.

In the event of a market discount on the payment date for any dividend, the Plan Administrator will have until the last business day before the next date on which the Common Shares trade on an "ex-dividend" basis or in no event more than 30 days after the record date for such dividend, whichever is sooner (the "last purchase date"), to invest the dividend amount in Common Shares acquired in open-market purchases. If, before the Plan Administrator has completed its open-market purchases, the market price of a Common Share exceeds the NAV per Common Share, the average per Common Share purchase price paid by the Plan Administrator may exceed the NAV of the Common Shares, resulting in the acquisition of fewer Common Shares than if the dividend had been paid in newly issued Common Shares on the dividend payment date. Because of the foregoing difficulty with respect to open-market purchases,

if the Plan Administrator is unable to invest the full dividend amount in open-market purchases during the purchase period or if the market discount shifts to a market premium during the purchase period, the Plan Administrator may cease making open-market purchases and may invest the uninvested portion of the dividend amount in newly issued Common Shares at the NAV per Common Share at the close of business on the last purchase date provided that, if the NAV is less than or equal to 95% of the then current market price per Common Share, the dollar amount of the dividend will be divided by 95% of the market price on the date of issuance for purposes of determining the number of Common Shares issuable under the Plan.

The Plan Administrator maintains all registered Shareholders' accounts in the Plan and furnishes written confirmation of all transactions in the accounts, including information needed by Shareholders for tax records. Common Shares in the account of each Plan participant generally will be held by the Plan Administrator in non-certificated form in the name of the Plan participant, although the Plan Administrator will issue certificates for whole Common Shares upon your request. Certificates for fractional Common Shares will not be issued.

In the case of Shareholders such as banks, brokers or nominees that hold Common Shares for others who are the beneficial owners, the Plan Administrator will administer the Plan on the basis of the number of Common Shares certified from time to time by the record Shareholder and held for the account of beneficial owners who participate in the Plan.

There will be no brokerage charges with respect to Common Shares issued directly by the Fund as a result of dividends payable either in Common Shares or in cash. However, each participant will

## Automatic Dividend Reinvestment Plan (Unaudited) (concluded)

pay a pro rata share of brokerage trading fees incurred with respect to the Plan Administrator's open-market purchases of Common Shares in connection with the reinvestment of dividends under the Plan.

Participants in the Plan may sell any or all of their Common Shares in their Plan accounts by contacting the Plan Administrator. The Plan Administrator currently charges \$15.00 for the transaction, plus \$0.10 per Common Share for this service. Participants also may withdraw their Common Shares from their Plan accounts and sell those Common Shares through their broker.

Neither the Fund nor the Plan Administrator will provide any advice, make any recommendations, or offer any opinion with respect to whether or not you should purchase or sell your Common Shares or otherwise participate in the Plan. You must make independent investment decisions based on your own judgment and research. The Common Shares held in Plan accounts are not subject to protection under the Securities Investor Protection Act of 1970.

Neither the Fund nor the Plan Administrator will be liable for any good faith act or for any good faith omission to act, including, without limitation, any claim or liability arising out of failure to terminate a participant's account upon the participant's death, the prices at which Common Shares are purchased or sold for a participant's account, the times when purchases or sales of Common Shares are made, or fluctuations in the market value of Common Shares. However, nothing contained in this provision affects a Shareholder's right to bring a cause of action based on alleged violations of the federal securities laws.

### Voting

Each Shareholder proxy will include those Common Shares purchased or received pursuant to the Plan. The Plan Administrator will forward all proxy solicitation materials to participants and vote proxies for Common Shares held pursuant to the Plan in accordance with the instructions of the participants.

### Taxation

The automatic reinvestment of dividends will not relieve participants of any federal, state or local income tax that may be payable (or required to be withheld) on such dividends.

### Amendments to Plan

The Fund reserves the right to suspend, amend or terminate the Plan at any time. All Shareholders of record, both participants and non-participants in the Plan, will be notified of any suspension, termination or significant amendment of the Plan. If the Plan is terminated, Common Shares held in the participants' accounts will be distributed to the participants. Any change in the source of purchase of Common Shares under the Plan from open market purchases or direct issuance by the Plan Administrator does not constitute an amendment to the Plan.

## THE SWISS HELVETIA FUND, INC.

### Independent Directors and Officers

Brian A. Berris <i>Chairman (Non-executive)</i>	David J. Marshall <i>Treasurer</i>
David R. Bock <sup>1</sup> <i>Director</i>	<i>Principal Financial Officer</i>
Richard A. Brealey <sup>2,3</sup> <i>Director</i>	Shanak Patnaik <i>Chief Compliance Officer</i>
Joseph S. Calhoun <sup>2</sup> <i>Director</i>	Carin F. Muhlbaum <i>Vice President</i>
Claus Helbig <sup>4</sup> <i>Director</i>	William P. Sauer <i>Vice President</i>
Fred J. Ricciardi <sup>2</sup> <i>Director</i>	Reid B. Adams <i>Chief Legal Officer</i>
Samuel B. Witt III, Esq. <i>Director</i>	<i>Secretary</i>
Mark A. Hemenetz <i>President</i>	Angel Lanier <i>Assistant Secretary</i>
<i>Principal Executive Officer</i>	

<sup>1</sup> Audit Committee Chair

<sup>2</sup> Audit Committee Member

<sup>3</sup> Pricing Committee Chair

<sup>4</sup> Governance/Nominating  
Committee Chair

### Investment Adviser

Schroder Investment Management North America, Inc.  
7 Bryant Park  
New York, NY 10018  
(800) 730-2932

### Investment Sub-adviser

Schroder Investment Management North America Ltd.  
31 Gresham Street  
London, EC2V 7QA United Kingdom

### Administrator

JPMorgan Chase Bank, N.A.

### Custodian

JPMorgan Chase Bank, N.A.

### Transfer Agent

American Stock Transfer & Trust Company  
59 Maiden Lane  
Plaza Level  
New York, NY 10038  
(888) 556-0425

### Legal Counsel

Proskauer Rose LLP

### Independent Registered Public Accounting Firm

Tait, Weller & Baker, LLP

### The Investment Adviser

The Swiss Helvetia Fund, Inc. (the "Fund") is managed by Schroder Investment Management North America Inc. ("SIMNA Inc.")

SIMNA Inc. is an investment adviser registered with the U.S. Securities & Exchange Commission (the "SEC"). It provides asset management products and services to a broad range of clients including Schroder Series Trust and Schroder Global Series Trust, investment companies registered with the SEC. SIMNA Inc. is part of a global asset management firm with approximately \$520.6 billion in assets under management as of March 31, 2017.

### Executive Offices

The Swiss Helvetia Fund, Inc.  
7 Bryant Park  
New York, NY 10018  
(800) 730-2932

### For inquiries and reports:

(800) 730-2932

email: [swzintermediary@schroders.com](mailto:swzintermediary@schroders.com)

### Website Address

[www.swzfund.com](http://www.swzfund.com)

### The Fund

The Fund is a non-diversified, closed-end investment company whose objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The Fund also may acquire and hold equity and equity-linked securities of non-Swiss companies in limited instances.

The Fund is listed on the New York Stock Exchange under the symbol "SWZ".

Net Asset Value is calculated daily by 6:15 P.M. (Eastern Time). The most recent calculation is available by accessing the Fund's website [www.swzfund.com](http://www.swzfund.com). Net Asset Value is also published weekly in *Barron's*, the Monday edition of *The Wall Street Journal* and the Sunday edition of *The New York Times*.

[THIS PAGE INTENTIONALLY LEFT BLANK]





**THE SWISS HELVETIA FUND, INC.**

Executive Offices  
7 Bryant Park  
New York, NY 10018  
(800) 730-2932  
[www.swzfund.com](http://www.swzfund.com)

SWZ QR 3-31-17



**A SWISS INVESTMENTS FUND**  
[WWW.SWZFUND.COM](http://WWW.SWZFUND.COM)

**QUARTERLY REPORT**

For the Period Ended  
March 31, 2017